

<b>Reference:</b>	FOI.1596.19
<b>Subject:</b>	Intra-vitreous vials/implants
<b>Date of Request:</b>	20 September 2019

**Requested**

Within your trust how many of the following intra-vitreous vials/implants have been used in the latest 4 months, if possible between May to August 2019;

- Ranibizumab
- Bevacizumab
- Aflibercept
- Fluocinolone
- Dexamethasone

**Response:**

Hywel Dda University Health Board (UHB) has provided the number of intra-vitreous vials/implants used within the requested period within the table overleaf:

Intra-vitreous vials/implants	Number
Ranibizumab	1791
Bevacizumab	0
Aflibercept	1055
Fluocinolone	0
Dexamethasone	35